Julia K Mader

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1367196/publications.pdf

Version: 2024-02-01

182225 182931 3,498 133 30 54 citations h-index g-index papers 143 143 143 3436 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	A Glycemia Risk Index (GRI) of Hypoglycemia and Hyperglycemia for Continuous Glucose Monitoring Validated by Clinician Ratings. Journal of Diabetes Science and Technology, 2023, 17, 1226-1242.	1.3	69
2	Needle Technology for Insulin Administration: A Century of Innovation. Journal of Diabetes Science and Technology, 2023, 17, 449-457.	1.3	6
3	Management of Type 1 Diabetes Mellitus Using Open-Source Automated Insulin Delivery During Pregnancy: A Case Series. Diabetes Technology and Therapeutics, 2022, 24, 227-230.	2.4	9
4	Impact of COVID-19 Vaccination on Glycemia in Individuals With Type 1 and Type 2 Diabetes: Substudy of the COVAC-DM Study. Diabetes Care, 2022, 45, e24-e26.	4.3	21
5	Humoral immune response to <scp>COVIDâ€19</scp> vaccination in diabetes is ageâ€dependent but independent of type of diabetes and glycaemic control: The prospective <scp>COVACâ€DM</scp> cohort study. Diabetes, Obesity and Metabolism, 2022, 24, 849-858.	2.2	45
6	Randomized Trial of Closed-Loop Control in Very Young Children with Type 1 Diabetes. New England Journal of Medicine, 2022, 386, 209-219.	13.9	99
7	Accuracy Assessment of the GlucoMen® Day CGM System in Individuals with Type 1 Diabetes: A Pilot Study. Biosensors, 2022, 12, 106.	2.3	6
8	Hybrid closed-loop glucose control compared with sensor augmented pump therapy in older adults with type 1 diabetes: an open-label multicentre, multinational, randomised, crossover study. The Lancet Healthy Longevity, 2022, 3, e135-e142.	2.0	38
9	Performance of intermittently scanned continuous glucose monitoring systems in people with type 1 diabetes: A pooled analysis. Diabetes, Obesity and Metabolism, 2022, 24, 522-529.	2.2	12
10	Medication errors in type 2 diabetes from patients' perspective. PLoS ONE, 2022, 17, e0267570.	1.1	1
11	Hypoâ€METRICS: Hypoglycaemia—MEasurement, ThResholds and ImpaCtS—A multiâ€country clinical study to define the optimal threshold and duration of sensorâ€detected hypoglycaemia that impact the experience of hypoglycaemia, quality of life and health economic outcomes: The study protocol. Diabetic Medicine, 2022, 39, .	1.2	11
12	Safely finishing a half marathon by an adult with typeÂ1 diabetes using a commercially available hybrid closedâ€loop system. Journal of Diabetes Investigation, 2021, 12, 450-453.	1.1	4
13	Safe and Sufficient Glycemic Control by Using a Digital Clinical Decision Support System for Patients With Type 2 Diabetes in a Routine Setting on General Hospital Wards. Journal of Diabetes Science and Technology, 2021, 15, 231-235.	1.3	7
14	Performance of three different continuous glucose monitoring systems in children with type 1 diabetes during a diabetes summer camp. Pediatric Diabetes, 2021, 22, 271-278.	1.2	10
15	Electronic Diabetes Management System Replaces Paper Insulin Chart: Improved Quality in Diabetes Inpatient Care Processes Due to Digitalization. Journal of Diabetes Science and Technology, 2021, 15, 222-230.	1.3	2
16	Application of Telemedicine in Diabetes Care: The Time is Now. Diabetes Therapy, 2021, 12, 629-639.	1.2	36
17	Glucose management for exercise using continuous glucose monitoring: should sex and prandial state be additional considerations? Reply to Yardley JE and Sigal RJ [letter]. Diabetologia, 2021, 64, 935-938.	2.9	4
18	Assessing the efficacy, safety and utility of closed-loop insulin delivery compared with sensor-augmented pump therapy in very young children with type 1 diabetes (KidsAPO2 study): an open-label, multicentre, multinational, randomised cross-over study protocol. BMJ Open, 2021, 11, e042790.	0.8	10

#	Article	IF	CITATIONS
19	Survival assessment of the <scp>extendedâ€wear</scp> insulin infusion set featuring lantern technology in adults with type 1 diabetes by the glucose clamp technique. Diabetes, Obesity and Metabolism, 2021, 23, 1402-1408.	2.2	9
20	Hybrid closed″oop glucose control with faster insulin aspart compared with standard insulin aspart in adults with type 1 diabetes: A doubleâ€blind, multicentre, multinational, randomized, crossover study. Diabetes, Obesity and Metabolism, 2021, 23, 1389-1396.	2.2	58
21	Hypoglycaemia detection and prediction techniques: AÂsystematic review on the latest developments. Diabetes/Metabolism Research and Reviews, 2021, 37, e3449.	1.7	23
22	Real-world data on metabolic effects of PCSK9 inhibitors in a tertiary care center in patients with and without diabetes mellitus. Cardiovascular Diabetology, 2021, 20, 89.	2.7	9
23	User Engagement With the CamAPS FX Hybrid Closed-Loop App According to Age and User Characteristics. Diabetes Care, 2021, 44, e148-e150.	4.3	12
24	A Practical Guide for the Management of Steroid Induced Hyperglycaemia in the Hospital. Journal of Clinical Medicine, 2021, 10, 2154.	1.0	35
25	Efficient and safe glycaemic control with basalâ€bolus insulin therapy during fasting periods in hospitalized patients with type 2 diabetes using decision support technology: A post hoc analysis. Diabetes, Obesity and Metabolism, 2021, 23, 2161-2169.	2.2	1
26	Design of clinical trials to assess diabetes treatment: Minimum duration of continuous glucose monitoring data to estimate timeâ€inâ€ranges with the desired precision. Diabetes, Obesity and Metabolism, 2021, 23, 2446-2454.	2.2	10
27	Psychological Well-Being of Parents of Very Young Children With Type 1 Diabetes – Baseline Assessment. Frontiers in Endocrinology, 2021, 12, 721028.	1.5	5
28	Long-term trends of BMI and cardiometabolic risk factors among adults with type 1 diabetes: An observational study from the German/Austrian DPV registry. Diabetes Research and Clinical Practice, 2021, 178, 108973.	1.1	6
29	Safe use of a onceâ€aâ€week glucagonâ€like peptideâ€1 receptor agonist in a 16â€yearâ€old girl with type 2 dial when approved therapy options fail. Clinical Case Reports (discontinued), 2021, 9, e04811.	petes 0.2	1
30	Not All Type-2-Diabetes Patients Increase Body Mass Index After Initiating Insulin: Results of Latent Class Analysis from the DPV Registry. Diabetes Technology and Therapeutics, 2021, 23, 799-806.	2.4	1
31	Renal Complications and Duration of Diabetes: An International Comparison in Persons with Type 1 Diabetes. Diabetes Therapy, 2021, 12, 3093-3105.	1.2	3
32	A Mathematical Formula to Determine the Minimum Continuous Glucose Monitoring Duration to Assess Time-in-ranges: Sensitivity Analysis Over the Parameters., 2021, 2021, 1435-1438.		1
33	Choosing the duration of continuous glucose monitoring for reliable assessment of time in range: A new analytical approach to overcome the limitations of correlationâ€based methods. Diabetic Medicine, 2021, , e14758.	1.2	1
34	Evaluating Glucose Control With a Novel Composite Continuous Glucose Monitoring Index. Journal of Diabetes Science and Technology, 2020, 14, 277-283.	1.3	20
35	scanned CGM (isCGM) systems in type 1 diabetes: position statement of the European Association for the Study of Diabetes (EASD) and of the International Society for Pediatric and Adolescent Diabetes (ISPAD) endorsed by JDRF and supported by the American Diabetes Association (ADA). Diabetologia, 2020,	2.9	102
36	Glucose management for exercise using continuous glucose monitoring (<scp>CGM < /scp>) and intermittently scanned <scp>CGM < /scp> (<scp>isCGM < /scp>) systems in type 1 diabetes: position statement of the European Association for the Study of Diabetes (<scp>EASD < /scp>) and of the International Society for Pediatric and Adolescent Diabetes (<scp>ISPAD < /scp>) endorsed by <scp>. Pediatric Diabetes, 2020, 21, 1375-1393.</scp></scp></scp></scp></scp></scp>	1.2	46

#	Article	IF	CITATIONS
37	Accuracy and stability of an arterial sensor for glucose monitoring in a porcine model using glucose clamp technique. Scientific Reports, 2020, 10, 6604.	1.6	2
38	Study protocol for assessing the user acceptance, safety and efficacy of a tablet-based workflow and decision support system with incorporated basal insulin algorithm for glycaemic management in participants with type 2 diabetes receiving home health care: A single-centre, open-label, uncontrolled proof-of-concept study. Contemporary Clinical Trials Communications, 2020, 19, 100620.	0.5	3
39	An analytical approach to determine the optimal duration of continuous glucose monitoring data required to reliably estimate time in hypoglycemia. Scientific Reports, 2020, 10, 18180.	1.6	9
40	Improved glycaemic variability and basal insulin dose reduction during a running competition in recreationally active adults with type 1 diabetes—A single-centre, prospective, controlled observational study. PLoS ONE, 2020, 15, e0239091.	1.1	7
41	SAT-LB71 Is Late Diagnosis of Postsurgical Hypoparathyroidism the Rule, Not the Exception?. Journal of the Endocrine Society, 2020, 4, .	0.1	0
42	Fracture risk in patients with type 2 diabetes aged ≥50Âyears related to HbA1c, acute complications, BMI and SGLT2i-use in the DPV registry. Journal of Diabetes and Its Complications, 2020, 34, 107664.	1.2	4
43	People with type 1 diabetes and impaired awareness of hypoglycaemia have a delayed reaction to performing a glucose scan during hypoglycaemia: a prospective observational study. Diabetic Medicine, 2020, 37, 2153-2159.	1.2	1
44	Two Subsequent Pregnancies in a Woman With Type 1 Diabetes: Artificial Pancreas Was a Gamechanger. Journal of Diabetes Science and Technology, 2020, $14,972-973$.	1.3	20
45	Duration of Hybrid Closed-Loop Insulin Therapy to Achieve Representative Glycemic Outcomes in Adults With Type 1 Diabetes. Diabetes Care, 2020, 43, e38-e39.	4.3	14
46	Interpreting the recent consensus on time in range for interstitial glucose right – Or wrong?. Diabetes Research and Clinical Practice, 2020, 162, 108106.	1.1	0
47	Personal Experiences With Coronavirus Disease 2019 and Diabetes: The Time for Telemedicine is Now. Journal of Diabetes Science and Technology, 2020, 14, 752-753.	1.3	9
48	877-P: Limits of Correlation Coefficient Analysis in Determining the Minimal Duration of CGM Data Needed to Estimate Time Below Range. Diabetes, 2020, 69, .	0.3	4
49	712-P: Safety and Efficacy of 36 Hours Prolonged Fasting on Glucose Metabolism in People with Type 1 Diabetes: A Crossover Trial. Diabetes, 2020, 69, .	0.3	0
50	888-P: Day vs. Nighttime Performance of Continuous Glucose Monitoring Systems in Children with Type 1 Diabetes during a Diabetes Summer Camp. Diabetes, 2020, 69, .	0.3	0
51	24-OR: Electronic Decision Support for Insulin Therapy Is Safe and Efficient in Inpatients with Type 2 Diabetes. Diabetes, 2020, 69, 24-OR.	0.3	0
52	157-OR: People with Type 1 Diabetes and Impaired Awareness of Hypoglycemia Have a Delayed Reaction to Perform a Glucose Scan during Hypoglycemia: A Prospective Observational Study. Diabetes, 2020, 69, .	0.3	0
53	Feasibility and safety of using an automated decision support system for insulin therapy inÂthe treatment of steroidâ€induced hyperglycemia in patients with acute graftâ€versusâ€host disease: A randomized trial. Journal of Diabetes Investigation, 2019, 10, 339-342.	1.1	8
54	Patients with healed diabetic foot ulcer represent a cohort at highest risk for future fatal events. Scientific Reports, 2019, 9, 10325.	1.6	25

#	Article	IF	CITATIONS
55	Feasibility of Blood Glucose Management Using Intra-Arterial Glucose Monitoring in Combination with an Automated Insulin Titration Algorithm in Critically III Patients. Diabetes Technology and Therapeutics, 2019, 21, 581-588.	2.4	3
56	Home Use of Day-and-Night Hybrid Closed-Loop Insulin Delivery in Very Young Children: A Multicenter, 3-Week, Randomized Trial. Diabetes Care, 2019, 42, 594-600.	4.3	79
57	Event Rates and Risk Factors for the Development of Diabetic Ketoacidosis in Adult Patients With Type 1 Diabetes: Analysis From the DPV Registry Based on 46,966 Patients. Diabetes Care, 2019, 42, e34-e36.	4.3	22
58	Young Children Have Higher Variability of Insulin Requirements: Observations During Hybrid Closed-Loop Insulin Delivery. Diabetes Care, 2019, 42, 1344-1347.	4.3	51
59	Reduced burden of diabetes and improved quality of life: Experiences from unrestricted dayâ€andâ€night hybrid closedâ€loop use in very young children with type 1 diabetes. Pediatric Diabetes, 2019, 20, 794-799.	1.2	72
60	Developing a Simple 3-Day Insulin Delivery Device to Meet the Needs of People With Type 2 Diabetes. Journal of Diabetes Science and Technology, 2019, 13, 11-19.	1.3	8
61	Insulin Bolus Administration in Insulin Pump Therapy: Effect of Bolus Delivery Speed on Insulin Absorption from Subcutaneous Tissue. Diabetes Technology and Therapeutics, 2019, 21, 44-50.	2.4	10
62	GlucoTabâ€guided insulin therapy using insulin glargine U300 enables glycaemic control with low risk of hypoglycaemia in hospitalized patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 584-591.	2.2	16
63	A headâ€toâ€head comparison of personal and professional continuous glucose monitoring systems in people with type 1 diabetes: Hypoglycaemia remains the weak spot. Diabetes, Obesity and Metabolism, 2019, 21, 1043-1048.	2.2	18
64	A typical clinical presentation of a woman with Köbberling Syndrome. Polish Archives of Internal Medicine, 2019, 129, 414-416.	0.3	2
65	96-LB: Effectiveness of FreeStyle Libre Flash Glucose Monitoring System Observed in Real-World, Chart Review Study in Austria, in Adults with Type 2 Diabetes. Diabetes, 2019, 68, 96-LB.	0.3	0
66	1039-P: Hybrid Closed-Loop in Adults with Type 1 Diabetes: Impact of Baseline A1c on Glucose Outcomes and Insulin Delivery. Diabetes, 2019, 68, 1039-P.	0.3	0
67	115-LB: Optimal Sampling Duration of Hybrid Closed-Loop Therapy to Determine Long-Term Glycemic Control in Adults with Type 1 Diabetes. Diabetes, 2019, 68, .	0.3	0
68	951-P: A Clinical Decision Support System for Basal-Bolus Insulin Therapy Is Moving to Hospital Routine Care: Efficacy, Safety, and Usability Confirmed. Diabetes, 2019, 68, 951-P.	0.3	0
69	Hypoglycaemia incidence and recovery during home use of hybrid closedâ€loop insulin delivery in adults with type 1 diabetes. Diabetes, Obesity and Metabolism, 2018, 20, 2004-2008.	2.2	19
70	Impact of C-Peptide Status on the Response of Glucagon and Endogenous Glucose Production to Induced Hypoglycemia in T1DM. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1408-1417.	1.8	23
71	A prolonged run-in period of standard subcutaneous microdialysis ameliorates quality of interstitial glucose signal in patients after major cardiac surgery. Scientific Reports, 2018, 8, 1262.	1.6	3
72	Visceral leishmaniasis in a patient with diabetes mellitus type 2 and discrete bicytopenia. Clinical Case Reports (discontinued), 2018, 6, 78-81.	0.2	7

#	Article	IF	Citations
73	Bolusing frequency and amount impacts glucose control during hybrid closedâ€loop. Diabetic Medicine, 2018, 35, 347-351.	1.2	6
74	Improved glycaemic control and treatment satisfaction with a simple wearable 3â€day insulin delivery device among people with Type 2 diabetes. Diabetic Medicine, 2018, 35, 1448-1456.	1.2	15
75	Shortâ€term effects of dapagliflozin on insulin sensitivity, postprandial glucose excursion and ketogenesis in type 1 diabetes mellitus: A randomized, placeboâ€controlled, double blind, crossâ€over pilot study. Diabetes, Obesity and Metabolism, 2018, 20, 2685-2689.	2.2	5
76	Diabetes Management in Hospitalized Patients with Type 2 Diabetes (T2D) during Fasting Periods. Diabetes, 2018, 67, 2280-PUB.	0.3	2
77	Looking Beyond HbA1c—Evaluating Glycaemic Control during Closed-Loop Use in Type 1 Diabetes. Diabetes, 2018, 67, .	0.3	0
78	Assessment of Infusion Set Survival of the Newly Developed Lantern Catheter in Type 1 Diabetes by Glucose CLA Technique. Diabetes, 2018, 67, 89-LB.	0.3	0
79	A Novel Composite Glucose Index (COGI) for Evaluating Closed-Loop Performance in Type 1 Diabetes. Diabetes, 2018, 67, .	0.3	1
80	Rapid Benefits of Structured Optimization and Sensor-Augmented Insulin Pump Therapy in Adults With Type 1 Diabetes. Journal of Diabetes Science and Technology, 2017, 11, 180-181.	1.3	3
81	Day-and-night glycaemic control with closed-loop insulin delivery versus conventional insulin pump therapy in free-living adults with well controlled type 1 diabetes: an open-label, randomised, crossover study. Lancet Diabetes and Endocrinology,the, 2017, 5, 261-270.	5.5	120
82	Evaluation of subcutaneous glucose monitoring systems under routine environmental conditions in patients with type 1 diabetes. Diabetes, Obesity and Metabolism, 2017, 19, 1051-1055.	2.2	111
83	Hyperglycaemia within the first month after allogeneic haematopoietic stem-cell transplantation is an independent risk factor for overall survival in patients with acute myeloid leukaemia. Diabetes and Metabolism, 2017, 43, 560-562.	1.4	4
84	Faster insulin action is associated with improved glycaemic outcomes during closedâ€loop insulin delivery and sensorâ€augmented pump therapy in adults with type 1 diabetes. Diabetes, Obesity and Metabolism, 2017, 19, 1485-1489.	2.2	7
85	Closing the Loop in Adults, Children and Adolescents With Suboptimally Controlled Type 1 Diabetes Under Free Living Conditions: A Psychosocial Substudy. Journal of Diabetes Science and Technology, 2017, 11, 1080-1088.	1.3	99
86	Early Hyperglycemia after Initiation of Glucocorticoid Therapy Predicts Adverse Outcome in Patients with Acute Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2017, 23, 1186-1192.	2.0	13
87	Cover Image, Volume 19, Issue 10. Diabetes, Obesity and Metabolism, 2017, 19, i-i.	2.2	0
88	Combined metformin-associated lactic acidosis and euglycemic ketoacidosis. Wiener Klinische Wochenschrift, 2017, 129, 646-649.	1.0	14
89	First application of a transcutaneous optical single-port glucose monitoring device in patients with type 1 diabetes mellitus. Biosensors and Bioelectronics, 2017, 88, 240-248.	5.3	19
90	A Mobile Computerized Decision Support System to Prevent Hypoglycemia in Hospitalized Patients With Type 2 Diabetes Mellitus. Journal of Diabetes Science and Technology, 2017, 11, 20-28.	1.3	17

#	Article	IF	CITATIONS
91	Behavioral Patterns and Associations with Glucose Control During 12-Week Randomized Free-Living Clinical Trial of Day and Night Hybrid Closed-Loop Insulin Delivery in Adults with Type 1 Diabetes. Diabetes Technology and Therapeutics, 2017, 19, 433-437.	2.4	11
92	Accuracy of Continuous Glucose Monitoring (CGM) during Continuous and High-Intensity Interval Exercise in Patients with Type 1 Diabetes Mellitus. Nutrients, 2016, 8, 489.	1.7	45
93	Impact of errors in paper-based and computerized diabetes management with decision support for hospitalized patients with type 2 diabetes. A post-hoc analysis of a before and after study. International Journal of Medical Informatics, 2016, 90, 58-67.	1.6	27
94	Pharmacokinetic Properties of Liraglutide as Adjunct to Insulin in Subjects with TypeÂ1 Diabetes Mellitus. Clinical Pharmacokinetics, 2016, 55, 1457-1463.	1.6	10
95	Variability of Insulin Requirements Over 12 Weeks of Closed-Loop Insulin Delivery in Adults With Type 1 Diabetes. Diabetes Care, 2016, 39, 830-832.	4.3	49
96	Variability of Basal Rate Profiles in Insulin Pump Therapy and Association with Complications in Type 1 Diabetes Mellitus. PLoS ONE, 2016, 11, e0150604.	1.1	14
97	Standardized Glycemic Management with a Computerized Workflow and Decision Support System for Hospitalized Patients with Type 2 Diabetes on Different Wards. Diabetes Technology and Therapeutics, 2015, 17, 685-692.	2.4	42
98	Taking a Closer Look—Continuous Glucose Monitoring in Non-Critically Ill Hospitalized Patients with Type 2 Diabetes Mellitus Under Basal-Bolus Insulin Therapy. Diabetes Technology and Therapeutics, 2015, 17, 611-618.	2.4	36
99	Effects of Vitamin D on Blood Pressure and Cardiovascular Risk Factors. Hypertension, 2015, 65, 1195-1201.	1.3	152
100	Novel Simple Insulin Delivery Device Reduces Barriers to Insulin Therapy in Type 2 Diabetes. Journal of Diabetes Science and Technology, 2015, 9, 581-587.	1.3	10
101	Accuracy of Continuous Glucose Monitoring During Three Closed-Loop Home Studies Under Free-Living Conditions. Diabetes Technology and Therapeutics, 2015, 17, 801-807.	2.4	33
102	Accuracy of two continuous glucose monitoring systems: a headâ€toâ€head comparison under clinical research centre and daily life conditions. Diabetes, Obesity and Metabolism, 2015, 17, 343-349.	2.2	116
103	Home Use of an Artificial Beta Cell in Type 1 Diabetes. New England Journal of Medicine, 2015, 373, 2129-2140.	13.9	397
104	A toolbox to improve algorithms for insulin-dosing decision support. Applied Clinical Informatics, 2014, 05, 548-556.	0.8	3
105	Day and Night Home Closed-Loop Insulin Delivery in Adults With Type 1 Diabetes: Three-Center Randomized Crossover Study. Diabetes Care, 2014, 37, 1931-1937.	4.3	113
106	Assessing the effectiveness of 3 months day and night home closed-loop insulin delivery in adults with suboptimally controlled type 1 diabetes: a randomised crossover study protocol. BMJ Open, 2014, 4, e006075-e006075.	0.8	12
107	Efficacy, usability and sequence of operations of a workflowâ€integrated algorithm for basal–bolus insulin therapy in hospitalized type 2 diabetes patients. Diabetes, Obesity and Metabolism, 2014, 16, 137-146.	2.2	26
108	A Feasibility Study of a 3-Day Basal-Bolus Insulin Delivery Device in Individuals With Type 2 Diabetes. Diabetes Care, 2014, 37, 1476-1479.	4.3	14

#	Article	IF	CITATIONS
109	Awareness of chronic kidney disease in Austria: a frequently under-recognized clinical picture. Wiener Klinische Wochenschrift, 2013, 125, 362-367.	1.0	5
110	Accuracy and Reliability of Continuous Glucose Monitoring Systems: A Head-to-Head Comparison. Diabetes Technology and Therapeutics, 2013, 15, 721-726.	2.4	70
111	Day and Night Closed-Loop Control in Adults With Type 1 Diabetes. Diabetes Care, 2013, 36, 3882-3887.	4.3	95
112	Real-Time Improvement of Continuous Glucose Monitoring Accuracy: The smart sensor concept. Diabetes Care, 2013, 36, 793-800.	4.3	86
113	A Comparison of the Steady-State Pharmacokinetic and Pharmacodynamic Profiles of 100 and 200ÂU/mL Formulations of Ultra-Long-Acting Insulin Degludec. Clinical Drug Investigation, 2013, 33, 515-521.	1.1	81
114	A direct comparison of the pharmacodynamic properties ofÂinsulin detemir and neutral protamine lispro insulin in patients with type 1 diabetes. Diabetes, Obesity and Metabolism, 2013, 15, 241-245.	2.2	7
115	Enhanced Absorption of Insulin Aspart as the Result of a Dispersed Injection Strategy Tested in a Randomized Trial in Type 1 Diabetic Patients. Diabetes Care, 2013, 36, 780-785.	4.3	22
116	Optimising the glucose sampling performance of an intravascular microdialysisbased continuous glucose monitoring device for use in hospital settings. Biomedizinische Technik, 2013, 58 Suppl 1, .	0.9	2
117	Continuous Glucose Monitoring Accuracy Results Vary between Assessment at Home and Assessment at the Clinical Research Center. Journal of Diabetes Science and Technology, 2012, 6, 1103-1106.	1.3	24
118	Microdialysisâ€"A versatile technology to perform metabolic monitoring in diabetes and critically ill patients. Diabetes Research and Clinical Practice, 2012, 97, 112-118.	1,1	17
119	Occult Pneumothorax on Chest X-ray. American Journal of Emergency Medicine, 2011, 29, 959.e3-959.e4.	0.7	2
120	Lipidâ€Heparin Infusion Suppresses the ILâ€10 Response to Trauma in Subcutaneous Adipose Tissue in Humans. Obesity, 2011, 19, 715-721.	1.5	8
121	The effect of vitamin D supplementation on peripheral regulatory T cells and \hat{I}^2 cell function in healthy humans: a randomized controlled trial. Diabetes/Metabolism Research and Reviews, 2011, 27, 942-945.	1.7	97
122	A Stepwise Approach toward Closed-Loop Blood Glucose Control for Intensive Care Unit Patients: Results from a Feasibility Study in Type 1 Diabetic Subjects Using Vascular Microdialysis with Infrared Spectrometry and a Model Predictive Control Algorithm. Journal of Diabetes Science and Technology, 2011, 5, 901-905.	1.3	11
123	PS12 - 62. Continuous glucose monitoring accuracy assessed at home is seemingly better than when assessed at the clinical research centre. Nederlands Tijdschrift Voor Diabetologie, 2011, 9, 133-133.	0.0	0
124	Assessment of different techniques for subcutaneous glucose monitoring in Type 1 diabetic patients during â€~realâ€life' glucose excursions. Diabetic Medicine, 2010, 27, 332-338.	1.2	10
125	Adipose tissue, inflammation and cardiovascular disease. Revista Da Associação Médica Brasileira, 2010, 56, 116-121.	0.3	68
126	Interleukin-6 produced in subcutaneous adipose tissue is linked to blood pressure control in septic patients. Cytokine, 2010, 50, 284-291.	1.4	12

#	ARTICLE	IF	CITATIONS
127	An Automated Discontinuous Venous Blood Sampling System for Ex Vivo Glucose Determination in Humans. Journal of Diabetes Science and Technology, 2009, 3, 110-116.	1.3	1
128	Hypoglycaemic coma due to falsely high point-of-care glucose measurements in an ICU-patient with peritoneal dialysis: a critical incidence report. Intensive Care Medicine, 2009, 35, 571-572.	3.9	13
129	A novel automated discontinuous venous blood monitoring system for ex vivo glucose determination in humans. Biosensors and Bioelectronics, 2009, 24, 2239-2245.	5.3	8
130	Physiological Hyperinsulinemia Has No Detectable Effect on Access of Macromolecules to Insulin-Sensitive Tissues in Healthy Humans. Diabetes, 2007, 56, 2213-2217.	0.3	11
131	Subcutaneous adipose tissue exerts proinflammatory cytokines after minimal trauma in humans. American Journal of Physiology - Endocrinology and Metabolism, 2007, 293, E690-E696.	1.8	47
132	Monitoring Blood Glucose with Microdialysis of Interstitial Fluid in Critically III Children. Clinical Chemistry, 2007, 53, 536-537.	1.5	13
133	Clinical Evaluation of Alternative-Site Glucose Measurements in Patients After Major Cardiac Surgery. Diabetes Care, 2006, 29, 1275-1281.	4.3	46